Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1622215

Donghui Ran, Cheng Geng, Zhongming Cha, Xiaohan Nie, Abudouwaili Atigu, Chuankui Zhao, Xinjian Xu

{"title":"Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma.","authors":"Donghui Ran, Cheng Geng, Zhongming Cha, Xiaohan Nie, Abudouwaili Atigu, Chuankui Zhao, Xinjian Xu","doi":"10.3389/fonc.2025.1622215","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC).Methods: We retrospectively analyzed 3-year postoperative clinical data from 92 patients with PDAC who underwent curative resection between March 2020 and March 2022. Participants were allocated to either a control group (n = 40) receiving nab-paclitaxel plus gemcitabine (nab-P/GEM) or an experimental group (n = 52) receiving S-1 plus nab-paclitaxel plus gemcitabine. We compared overall survival (OS), disease-free survival (DFS), and adverse event (AE) incidence between groups.Results: The experimental group showed significantly longer median OS (28.9 vs. 20.9 months; HR 0.62, 95% CI 0.38-0.99; P = 0.049 by log-rank test) and DFS (19.5 vs. 13.6 months; HR 0.59, 95% CI 0.36-0.97; P = 0.036) compared with controls. The incidence of grade ≥3 AEs was significantly lower in the experimental group, including leukopenia (13.5% vs. 47.5%; P < 0.001) and neutropenia (15.4% vs. 70.0%; P < 0.001). Fewer patients in the experimental group required treatment discontinuation (1.9% vs. 12.5%) or dose modifications (13.5% vs. 65.0%).Conclusion: The S-1/nab-paclitaxel/gemcitabine triplet regimen appears to improve survival outcomes while demonstrating potentially favorable tolerability as adjuvant therapy for resected PDAC.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1622215"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1622215","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC).

Methods: We retrospectively analyzed 3-year postoperative clinical data from 92 patients with PDAC who underwent curative resection between March 2020 and March 2022. Participants were allocated to either a control group (n = 40) receiving nab-paclitaxel plus gemcitabine (nab-P/GEM) or an experimental group (n = 52) receiving S-1 plus nab-paclitaxel plus gemcitabine. We compared overall survival (OS), disease-free survival (DFS), and adverse event (AE) incidence between groups.

Results: The experimental group showed significantly longer median OS (28.9 vs. 20.9 months; HR 0.62, 95% CI 0.38-0.99; P = 0.049 by log-rank test) and DFS (19.5 vs. 13.6 months; HR 0.59, 95% CI 0.36-0.97; P = 0.036) compared with controls. The incidence of grade ≥3 AEs was significantly lower in the experimental group, including leukopenia (13.5% vs. 47.5%; P < 0.001) and neutropenia (15.4% vs. 70.0%; P < 0.001). Fewer patients in the experimental group required treatment discontinuation (1.9% vs. 12.5%) or dose modifications (13.5% vs. 65.0%).

Conclusion: The S-1/nab-paclitaxel/gemcitabine triplet regimen appears to improve survival outcomes while demonstrating potentially favorable tolerability as adjuvant therapy for resected PDAC.

查看原文本刊更多论文

S-1、nab-紫杉醇和吉西他滨三联方案在胰腺导管腺癌切除术患者中的疗效和安全性

目的：评价以s -1为基础的三联方案（nab-紫杉醇和吉西他滨）作为根治性胰腺导管腺癌（PDAC）切除术后辅助治疗的安全性、可行性和有效性。方法：我们回顾性分析了2020年3月至2022年3月期间接受根治性切除的92例PDAC患者的术后3年临床资料。参与者被分配到对照组（n = 40），接受nab-紫杉醇加吉西他滨（nabp /GEM），或实验组（n = 52），接受S-1 + nab-紫杉醇加吉西他滨。我们比较了两组间的总生存期（OS）、无病生存期（DFS）和不良事件（AE）发生率。结果：实验组的中位OS（28.9个月比20.9个月；HR 0.62, 95% CI 0.38-0.99； log-rank检验P = 0.049）和DFS（19.5个月比13.6个月；HR 0.59, 95% CI 0.36-0.97; P = 0.036）较对照组显著延长。实验组≥3级ae的发生率明显低于对照组，包括白细胞减少症（13.5%比47.5%,P < 0.001）和中性粒细胞减少症（15.4%比70.0%,P < 0.001）。实验组中需要停药（1.9% vs. 12.5%）或调整剂量（13.5% vs. 65.0%）的患者较少。结论：S-1/nab-紫杉醇/吉西他滨三联方案似乎改善了生存结果，同时显示出潜在的良好耐受性，可作为切除PDAC的辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.